A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Shafique, Michael, Ismail‐Khan, Roohi, Extermann, Martine, Sullivan, Dan, Goodridge, Dawn, Boulware, David, Hogue, Deanna, Soliman, Hatem, Khong, Hung, Han, Hyo S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656474/
https://ncbi.nlm.nih.gov/pubmed/30996012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0231
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi